PreMD Reports Fiscal 2007 Results

    - PASA Data published in American Journal of Cardiology
    - FDA appeal progressing

    TORONTO, March 28 /CNW/ - Predictive medicine company PreMD Inc.
(TSX: PMD; Amex:   PME) today announced audited financial results for the year
ended December 31, 2007.
    "During 2007, PreMD faced many significant changes and challenges," said
Brent Norton, president and CEO. We made tremendous progress on several
fronts, including a License, Development and Supply Agreement with AstraZeneca
Pharmaceuticals LP for the marketing and distribution of our point-of-care
(POC) skin cholesterol test in the United States. We also successfully
penetrated the cosmetics industry as we recently signed an agreement with one
of the world's leading cosmetics company, which will enable us to further
explore the potential our technology holds in other viable markets. In
addition, we continue to achieve several clinical and scientific validations
related to both our cardiovascular and cancer franchises, including the
publication of our 'Increased Skin Cholesterol Identifies Individuals at
Increased Cardiovascular Risk: The Predictor of Advanced Subclinical
Atherosclerosis (PASA) Study' this week in the American Journal of Cardiology,
April 2008 edition."
    Dr. Norton continued, "despite these critical achievements, the company
faced difficulties, as we received a non-substantially equivalent (NSE) letter
from the US Food and Drug Administration (FDA) regarding our 510(k)
submission. We have appealed the FDA decision, including submitting a detailed
brief and meeting with them to present our case. We are pleased to have the
support of AstraZeneca Pharmaceuticals LP, as well as several leading
consultants, through the internal agency review process and we expect to hear
from the FDA with the next steps in the next 30 days. We also recently
completed a financing, which will enable us to move forward with our business
development initiatives, pending FDA clearance and the subsequent
commercialization of our products. We appreciate the patience and support of
our stakeholders, as we determine the most effective steps toward enhancing
shareholder value while evaluating the opportunities before us."

    Financial Review (All amounts are in Canadian dollars)

    The consolidated loss for the year ended December 31, 2007 was $6,316,000
or $(0.26) per share compared with a loss of $5,949,000 or $(0.27) per share
for the year ended December 31, 2006, an increase of $367,000.
    Total product sales of PREVU(*) Skin Cholesterol tests amounted to $41,000
in 2007 compared with $7,000 in 2006. License revenue was $53,000 in 2007
compared to $3,329,000 in 2006, a decrease of $3,276,000. License revenue
consists primarily of the upfront cash payments received in accordance with
the respective licensing agreements, which have been deferred and recognized
into income on a straight-line basis over the terms of the agreements. For
2007, the license revenue represents the amortization of the $533,000
(US$500,000) received upon signing of the license agreement with AstraZeneca
on July 13, 2007.

    Research and development expenses for the year decreased by $1,996,000 to
$2,778,000 from $4,774,000 in 2006. The variance for the year reflects:

    -   A decrease of $2,224,000 in spending on clinical trials for skin
        cholesterol and cancer to $347,000 from $2,571,000 in 2006, following
        the submission of the US FDA application;
    -   An decrease of $103,000 in product liability insurance due which is
        related to the reduced number of clinical trials undertaken in 2007;
    -   An increase of $175,000 in performance-based compensation expense
        resulting from achievement of milestones;
    -   An increase of $88,000 in product development and subcontract
        research as related to the validation of subcontract manufacturers
        for the skin cholesterol kits and the second-generation color reader,
        as well as for general product improvements;
    -   An increase of $37,000 in stock-based compensation, a non-cash
        expense, due to the vesting of options granted in prior years; and
    -   Minor changes in other development costs during the period.

    General and administration expenses amounted to $3,213,000 compared with
$3,025,000 in 2006, an increase of $188,000. The variance primarily reflects:

    -   An expense of nil in 2007 compared to $175,000 in 2006 for payments
        to amend the ColorectAlert License Agreement;
    -   An increase of $25,000 in distribution expenses (nil in 2006) related
        to the third-party warehouse expenses for storage of inventory;
    -   An increase of $178,000 in performance-based compensation expense
        resulting from achievement of milestones;
    -   A loss of $125,000 related to disposal of obsolete fixed assets
        related to skin cholesterol clinical trials;
    -   An increase of $57,000 in professional fees for legal, audit and
        consulting fees related to business development (including
        negotiation of the AstraZeneca agreement); and
    -   An increase of $17,000 in stock-based compensation for options and
        stock grants for administrative personnel and consultants resulting
        in a non-cash expense of $401,000 compared with $384,000 in 2006; and
    -   Minor changes in other general and administration costs during the

    Interest on convertible debentures (issued on August 30, 2005) amounted
to $663,000 in 2007 compared to $678,000 in 2006. The debentures bear interest
at an annual rate of 7%, payable quarterly in either cash or stock. In 2007,
$543,000 of the interest expense was paid in stock, rather than cash, compared
with $281,000 in 2006. Imputed interest of $1,002,000 (compared with $820,000
in 2006) represents the expense related to the accretion of the liability
component at an effective interest rate of 15%.
    Amortization expenses for equipment and acquired technology for 2007
amounted to $166,000 compared with $180,000 in 2006. The reduction in 2007
reflects the reduced amortization on the disposal of equipment related to skin
cholesterol clinical trials. Amortization of deferred financing fees amounted
to $139,000 in 2006.
    The gain on foreign exchange was $1,313,000 for 2007 compared to a loss
of $98,000 in 2006. The major reason for the increase was the impact of
foreign exchange rates on the convertible debentures which are repayable in US
dollars. This resulted in an unrealized gain of $1,355,000 on the convertible
    Recoveries of provincial scientific investment tax credits ("ITCs")
amounted to $140,000 for 2007 compared with $200,000 in 2006. The lower
accrual is based on the reduced spending on clinical trials in 2007.
    As at December 31, 2007, PreMD had cash, cash equivalents and short-term
investments totaling $1,190,000 ($3,276,000 as at December 31, 2006). To date,
we have financed our activities through product sales, license revenues, the
issuance of shares and convertible debentures and the recovery of provincial
ITCs. The Company reported a loss of $6,316,000 for the year ended
December 31, 2007, has a shareholders' deficiency of $4,420,000 as at
December 31, 2007 and has experienced significant operating losses and cash
outflows from operations since its inception. The Company has operating and
liquidity concerns due to its significant net losses and negative cash flows
from operations.
    On March 12, 2008, the Company issued, by way of private placement,
$1,435,294 senior unsecured debentures maturing on September 12, 2009 and
5,072,395 common share purchase warrants for gross proceeds of approximately
$1,220,000. Each common share purchase warrant expires in March 2013 and
entitles the holder to acquire one common share at a price of $0.2759 per
    Financial statements are attached to this press release. PreMD's complete
fiscal 2007 annual report is available at

    About PreMD

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include a line of non-invasive skin
cholesterol tests. PreMD's other skin cholesterol products include PREVU(*) LT,
a skin cholesterol test designed for use in the life insurance industry. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, Ontario and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For more information about PreMD, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions.
    In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
    Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.


                               (Tables Follow)

    PreMD Inc.
    Incorporated under the laws of Canada

                         CONSOLIDATED BALANCE SHEETS
                            (In Canadian dollars)

    As at December 31

                                                        2007          2006
                                                          $             $
    Cash and cash equivalents                          282,200       112,577
    Short-term investments                             907,768     3,163,482
    Accounts receivable                                  8,292        11,221
    Inventory                                           61,177       179,219
    Prepaid expenses and other receivables             758,715       570,773
    Investment tax credits receivable                  340,000       200,000
    Total current assets                             2,358,152     4,237,272
    Deferred financing fees, net of accumulated
     amortization of $174,863 in 2006                        -       347,589
    Capital assets, net                                 93,867       312,410
    Intangible assets, net of accumulated
     amortization of $991,473 (2006 - $915,027)        305,783       382,229
                                                     2,757,802     5,279,500

    Accounts payable                                   305,333       963,990
    Accrued liabilities                                765,312       932,372
    Current portion of deferred revenue                106,680             -
    Total current liabilities                        1,177,325     1,896,362
    Convertible debentures                           5,626,987     6,350,680
    Deferred revenue                                   373,380             -
    Total liabilities                                7,177,692     8,247,042

    Shareholders' deficiency
    Capital stock                                   29,120,655    25,263,480
    Contributed surplus                              3,098,928     2,521,915
    Equity component of convertible debentures       2,239,385     2,239,385
    Warrants                                         1,557,296     1,170,020
    Deficit                                        (40,436,154)  (34,162,342)
    Total shareholders' deficiency                  (4,419,890)   (2,967,542)
                                                     2,757,802     5,279,500

                                 PreMD Inc.

                            (In Canadian dollars)

    Years ended December 31
                                          2007          2006          2005
                                            $             $             $

    Product sales                         41,184         6,513       425,730
    License revenue                       53,340     3,328,827     1,153,308
                                          94,524     3,335,340     1,579,038
    Cost of product sales, including
     amortization of nil (2006 - nil;
     2005 - $3,456)                      140,261        36,824       428,650
                                         (45,737)    3,298,516     1,150,388

    Research and development           2,777,651     4,773,762     3,120,276
    General and administration         3,213,276     3,024,811     2,690,790
    Interest on convertible debentures   663,418       677,723       228,481
    Imputed interest on convertible
     debentures                        1,002,394       819,609       255,529
    Mark-to-market adjustment on
     derivative                           18,000             -             -
    Amortization                         165,753       319,205       252,804
    Loss (gain) on foreign exchange   (1,313,292)       97,746       (35,734)
                                       6,527,200     9,712,856     6,512,146

    Investment tax credits               140,000       200,000       198,923
    Interest                             117,125       265,369       173,130
                                         257,125       465,369       372,053
    Net loss and comprehensive loss
     for the year                     (6,315,812)   (5,948,971)   (4,989,705)

    Deficit, beginning of year       (34,162,342)  (28,213,371)  (23,223,666)
    Adjustment to opening deficit         42,000             -             -
    Deficit, end of year             (40,436,154)  (34,162,342)  (28,213,371)

    Basic and diluted loss per share      $(0.26)       $(0.27)       $(0.23)

    Weighted average number of
     common shares outstanding        24,326,078    21,663,698    21,487,008

                                 PreMD Inc.

                            (In Canadian dollars)

    Years ended December 31
                                          2007          2006          2005
                                            $             $             $

    Net loss and comprehensive
     loss for the year                (6,315,812)   (5,948,971)   (4,989,705)
    Add (deduct) items not
     involving cash
      Amortization                       165,753       319,205       256,260
      Stock-based compensation
       costs included in
        Research and development
         expense                         193,527       156,920       147,085
        General and administration
         expense                         400,821       383,767       421,812
      Loss (gain) on sale of capital
       assets                            139,669        (1,743)            -
      Imputed interest on
       convertible debentures          1,002,394       819,609       255,529
      Mark-to-market adjustment
       on derivative                      18,000             -             -
      Interest on convertible
       debentures paid in
       common shares                     543,312       281,462             -
      Loss (gain) on foreign exchange (1,288,160)       97,748       (35,734)
    Net change in non-cash working
     capital balances related to
     operations                       (1,011,237)    1,422,730    (1,061,397)
    Increase (decrease) in deferred
     revenue                             480,060    (2,609,315)     (301,885)
    Cash used in operating activities  (5,671,673)  (5,078,588)   (5,308,035)

    Short-term investments              2,218,115    4,589,356    (3,065,568)
    Purchase of trademark                       -     (150,000)            -
    Purchase of capital assets            (11,868)     (24,965)     (130,310)
    Proceeds from sale of capital
     assets                                 1,435        3,000             -
    Cash provided by (used in)
     investing activities               2,207,682    4,417,391    (3,195,878)

    Issuance of convertible
     debentures                                 -            -     9,827,616
    Financing fees                              -      (51,399)     (861,328)
    Issuance of capital stock, net of
     issue costs                        3,683,804            -       198,400
    Cash provided by (used in)
     financing activities               3,683,804      (51,399)    9,164,688

    Effect of exchange rate changes
     on cash and cash equivalents         (50,190)      51,974      (127,034)
    Net increase (decrease) in cash
     and cash equivalents during the
     year                                 169,623     (660,622)      533,741
    Cash and cash equivalents,
     beginning of year                    112,577      773,199       239,458
    Cash and cash equivalents, end
     of year                              282,200      112,577       773,199

    Represented by
    Cash                                  164,776      112,577       773,199
    Cash equivalents                      117,424            -             -
                                          282,200      112,577       773,199
    Supplemental cash flow information
    Cash paid during the year for
     interest                             120,106      396,261       228,481

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Michelle Rabba, Manager, Corporate
Communications, Tel: (416) 222-3449 ext. 25, Email:; Ron
Hosking, Vice President Finance and CFO, Tel: (416) 222-3449 ext. 24, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890